Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Pharmacogenet Genomics. 2016 Oct;26(10):473–480. doi: 10.1097/FPC.0000000000000238

Figure 1. Time to discontinuation of efavirenz for CNS side effects, stratified by genotype.

Figure 1

Panel A: all participants stratified by CYP2B6 metabolizer genotype; Panel B: White participants stratified by CYP2B6 metabolizer genotype; Panel C: Black participants stratified by CYP2B6 metabolizer genotype; Panel D: Participants with slow metabolizer genotype, stratified by race.